In this review:
Androgen deprivation + mitoxantrone in high-risk prostate cancer
Decipher predicts metastasis and prostate cancer-specific mortality
Clinical significance of androgen receptor mRNA quantification
Rad-IFNα/Syn3 for NMIBC
Chemoradiotherapy vs radiotherapy in MIBC
MIBC molecular subtypes
Pembrolizumab in cisplatin-ineligible advanced urothelial cancer
Dacomitinib for penile squamous cell carcinoma
Chemotherapy in non-seminomatous or combined germ cell testicular tumours
Intermediate-term outcomes from the DISSRM registry
Please login below to download this issue (PDF)